Avicanna (TSE:AVCN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avicanna Inc., a leader in cannabinoid-based biopharmaceuticals, will present at the Life Science Investor Forum on June 20, 2024, offering insights into its first EBITDA positive quarter and a 314% revenue increase year-over-year. CEO Aras Azadian will discuss recent achievements, including the approval of their Trunerox® drug, and engage in a fire-side chat with analyst Brad Sorensen. The event will provide a platform for live Q&A and will be available as an archived webcast post-conference.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.